Exon skipping therapy for Duchenne muscular dystrophy.

[1]  Christophe Béroud,et al.  The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations , 2015, Human mutation.

[2]  V. Ricotti,et al.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.

[3]  R. Mirabile,et al.  Species-specific Inflammatory Responses as a Primary Component for the Development of Glomerular Lesions in Mice and Monkeys Following Chronic Administration of a Second-generation Antisense Oligonucleotide , 2014, Toxicologic pathology.

[4]  V. Forin,et al.  Respiratory muscle decline in duchenne muscular dystrophy , 2014, Pediatric pulmonology.

[5]  G. Comi,et al.  6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes , 2014, PloS one.

[6]  K. Flanigan,et al.  Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial , 2013, Neuromuscular Disorders.

[7]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[8]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[9]  R. Kole,et al.  Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. , 2012, Discovery medicine.

[10]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[11]  F. Muntoni,et al.  Targeting RNA to treat neuromuscular disease , 2011, Nature Reviews Drug Discovery.

[12]  P. Sazani,et al.  Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy , 2011, International journal of toxicology.

[13]  P. Sazani,et al.  Chemical and Mechanistic Toxicology Evaluation of Exon Skipping Phosphorodiamidate Morpholino Oligomers in mdx Mice , 2011, International journal of toxicology.

[14]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[15]  T. Coté,et al.  Duchenne muscular dystrophy: Drug development and regulatory considerations , 2010, Muscle & nerve.

[16]  P. Sazani,et al.  Safety Pharmacology and Genotoxicity Evaluation of AVI-4658 , 2010, International journal of toxicology.

[17]  A. Levin,et al.  Toxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man , 2007 .

[18]  Jiun Wang,et al.  CpG-Independent Synergistic Induction of β-Chemokines and a Dendritic Cell Phenotype by Orthophosphorothioate Oligodeoxynucleotides and Granulocyte-Macrophage Colony-Stimulating Factor in Elutriated Human Primary Monocytes1 , 2005, The Journal of Immunology.

[19]  H. Kwon,et al.  CG sequence- and phosphorothioate backbone modification-dependent activation of the NF-kappaB-responsive gene expression by CpG-oligodeoxynucleotides in human RPMI 8226 B cells. , 2004, Molecular immunology.

[20]  S. Agrawal,et al.  Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides , 1999, Neuromuscular Disorders.

[21]  S. Agrawal,et al.  Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Z. Dominski,et al.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.